Autism Spectrum Disorder Treatment Market, Opportunity, Growth Drivers, Industry Trend Analysis and Forecast, 2024-2032

Description

The Global Autism Spectrum Disorder (ASD) Treatment Market was valued at USD 34.1 billion in 2023 and is projected to grow at a CAGR of 4.8% from 2024 to 2032. Several factors drive this market growth, notably the rising prevalence of ASD, which is increasingly shaped by enhanced diagnostic criteria, growing awareness, and genetic influences.

As awareness of ASD rises, more individuals receive diagnoses, fueling a global demand for effective treatments. For example, the Centers for Disease Control and Prevention (CDC) reports that about 1 in 54 children in the U.S. is diagnosed with ASD, marking a notable uptick in diagnosis rates over the last decade. This diagnostic surge has catalyzed innovations in treatment methods, leading to the creation of behavioral therapies, pharmacological solutions, and digital therapeutics, further propelling market growth.

Advancements in diagnostic tools help in the growth of the ASD treatment industry. As these technologies evolve, they enhance the ability to detect ASD earlier, resulting in more diagnoses. This uptick in diagnosed cases amplifies the demand for treatments, fueling market expansion. Moreover, increased awareness among healthcare professionals and parents, coupled with advanced diagnostic tools, has led to a rise in screenings and diagnoses of ASD. This is especially significant as it brings attention to previously underdiagnosed cases, broadening the market for ASD treatments.

The overall industry is divided into treatment type, disease, age group, end-use, and region.

The market is categorized by treatment type into drugs, therapy, and assistive applications. Within the drugs category, there are antipsychotic drugs, selective serotonin reuptake inhibitors, stimulants, and others. The therapy segment includes behavior and communication therapies, chelation therapy, and more. In 2023, the drugs segment led the market, achieving a valuation of USD 16.8 billion. This segment is vital for managing ASD-related symptoms, including behavioral challenges and communication issues, as well as co-occurring conditions like anxiety.

ASD treatment market categorizes diseases into autistic disorder, Asperger syndrome, pervasive developmental disorder (PDD), and others. In 2023, the autistic disorder segment held a dominant market share of 52.2%. This segment is essential for catering to individuals with more pronounced autism challenges. Treatments here combine behavioral therapies, pharmacological methods, and supportive services, all aimed at improving life quality and developmental results.

Autism spectrum disorder treatment market segments by age into children and adults. In 2023, the children segment led with a valuation of USD 25.3 billion. This dominance is attributed to heightened awareness, timely diagnoses, and a growing prevalence of ASD in children. Treatment avenues for children encompass behavioral therapies, communication strategies, educational initiatives, and medication oversight. Among these, behavioral therapies, especially applied behavior analysis, stand out, emphasizing skill enhancement through reinforcement techniques.

Product Code: 11087

Chapter 1 Methodology and Scope

1.1 Market scope and definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates and calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Increasing prevalence of autism
  - 3.2.1.2 Advancements in diagnostic tools
  - 3.2.1.3 Innovation in therapeutics
- 3.2.2 Industry pitfalls and challenges
  - 3.2.2.1 High cost of treatment
  - 3.2.2.2 Variability in treatment efficacy
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Future market trends
3.6 Porter's analysis
3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company matrix analysis
4.3 Competitive analysis of major market players
4.4 Competitive positioning matrix
4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Treatment Type, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 Drugs
- 5.2.1 Antipsychotic drugs
- 5.2.2 Selective serotonin reuptake inhibitors
- 5.2.3 Stimulants
- 5.2.4 Other drugs
5.3 Therapy
- 5.3.1 Behavior and communication therapies
- 5.3.2 Chelation therapy
- 5.3.3 Other therapies
5.4 Assistive apps

Chapter 6 Market Estimates and Forecast, By Disease, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Autistic disorder
6.3 Asperger syndrome
6.4 Pervasive developmental disorder (PDD)
6.5 Other diseases

Chapter 7 Market Estimates and Forecast, By Age Group, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 Children
7.3 Adult

Chapter 8 Market Estimates and Forecast, By End-use, 2021 - 2032 ($ Mn)

8.1 Key trends
8.2 Hospitals
8.3 Homecare settings
8.4 Rehabilitation centers
8.5 Other end-users

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

9.1 Key trends
9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 France
- 9.3.4 Spain
- 9.3.5 Italy
- 9.3.6 Netherlands
- 9.3.7 Rest of Europe
9.4 Asia Pacific
- 9.4.1 China
- 9.4.2 Japan
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 South Korea
- 9.4.6 Rest of Asia Pacific
9.5 Latin America
- 9.5.1 Brazil
- 9.5.2 Mexico
- 9.5.3 Argentina
- 9.5.4 Rest of Latin America
9.6 Middle East and Africa
- 9.6.1 South Africa
- 9.6.2 Saudi Arabia
- 9.6.3 UAE
- 9.6.4 Rest of Middle East and Africa

Chapter 10 Company Profiles

10.1 Service Provider
- 10.1.1 Autism Research Institute
- 10.1.2 Child Mind Institute, Inc.
- 10.1.3 Cleveland Clinic
- 10.1.4 Mayo Foundation for Medical Education and Research (MFMER).
- 10.1.5 The General Hospital Corporation
10.2 Medication Manufacturer
- 10.2.1 Axial Therapeutics Inc.
- 10.2.2 Bristol - Myers Squibb Company
- 10.2.3 Curemark LLC
- 10.2.4 Eli Lilly and Company
- 10.2.5 F. Hoffmann - La Roche Ltd.
- 10.2.6 Johnson and Johnson Services, Inc.
- 10.2.7 Novartis AG
- 10.2.8 Otsuka Pharmaceutical Co., Ltd.
- 10.2.9 PaxMedica
- 10.2.10 Pfizer Inc